GlobeNewswire Inc | Jul 8, 2021 07:02AM EDT

July 08, 2021

Widely Recognized Experts and AGTC Leadership Will Expand on Recent ACHM Phase 1/2 Clinical Trial Data and Discuss XLRP Milestones

Webcast Scheduled from 10:00 am - 1:00 pm ET

GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will host a virtual R&D Day from 10:00 am to 1:00 pm ET on Thursday, July 22, 2021.

AGTCs R&D Day will include a review of 12-month data from the highest dose groups in the ongoing Phase 1/2 clinical trials in X-linked retinitis pigmentosa (XLRP), which the Company announced in May, and expanded analysis of the recently reported data from the Companys ongoing Phase 1/2 clinical trial in achromatopsia (ACHM). The event also will include a discussion on light sensitivity and achromatopsia genetics, and an overview of the Companys manufacturing capabilities, including the 21,000 square foot current Good Manufacturing Practices (cGMP) manufacturing and quality control facility being built in Florida.

AGTC has seen highly encouraging 12-month data from our XLRP and ACHM clinical trials over the last two months, which gives us confidence in our abilities to execute the clinical and regulatory steps necessary to advance those therapies, said Sue Washer, President and Chief Executive Officer of AGTC. We look forward to taking a deeper dive into this data during our R&D Day and discussing preparations for late-stage development of our ACHM and XLRP candidates.

AGTC R&D Day Agenda:

-- Corporate OverviewSue Washer, President & Chief Executive Officer -- Pre-Clinical PipelineAdrian Timmers, Executive Director, In vivo Pharmacology and Toxicology -- Manufacturing and New Facility UpdateDave Knop, PhD, Vice President of Process DevelopmentStephen Potter, Chief Business Officer -- XLRP Indication, Phase 1/2 Data Robert Sisk, MD Associate Professor of Ophthalmology,University of CincinnatiandCincinnati Eye Institute, XLRP Phase 1/2 clinical trial investigator -- ACHM Indication, Phase 1/2 DataRachel Huckfeldt, MD, PhD, Assistant Professor of Ophthalmology, Harvard Medical School Department of Ophthalmology, Director,Inherited Retinal Degenerations Fellowship, Massachusetts Eye and Ear Infirmary -- Light Sensitivity and Achromatopsia GeneticsJoseph Carroll, PhD Richard O. Schultz, MD / Ruth Works Professor of Ophthalmology Professor of Ophthalmology & Visual Sciences, Biophysics, and Cell Biology, Neurobiology and Anatomy Director, Advanced Ocular Imaging Program

A live audio webcast of the presentation with accompanying slides can be accessible by visitingir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time.

Those interested in attending can RSVP by clicking the RSVP link in the Events & Presentations page of the investor section at AGTC.com.

The archived webcast and slide presentation will be available in the Events and Presentations section of the Company's website.

About AGTCAGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTCs most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build on the Companys industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

IR/PR CONTACTS:David Carey (IR) or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768 or (646) 871-8485david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:Stephen PotterChief Business OfficerApplied Genetic Technologies CorporationT: (617) 413-2754spotter@agtc.com